AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC)No ...
Targeted Oncology

Long-Term Pimicotinib Data Show Durable Responses in TGCT

The MANEUVER trial was a global, randomized, double-blind, placebo-controlled study evaluating pimicotinib in unresectable TGCT patients. Pimicotinib shows promising long-term efficacy in treating ...
The Manila Times

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session

Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and ...
The Manila Times

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') announced that at the 2025 European Society for Medical ...
The Caledonian-Record

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in ...

Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC)No ...

Why do heart surgeons wash their hands for exactly one minute before surgery

Heart surgeons meticulously scrub their hands for precisely one minute before each operation. This scientifically backed ...

Oryzon Genomics, S.A.: ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder

Provides clarity on the aspects to incorporateCompany to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN ...

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not ha…

Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus®, the only oral GLP-1 ...

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously ...
Agence France-Presse

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the ...

The global Phase 3 MOTION study (NCT05059262) aims to evaluate the efficacy and safety of vimseltinib for the treatment of TGCT in cases where surgical removal of the tumor is not an option.
CURE

Durable Gleevec Benefit Doubles Survival in Advanced GIST

Long-term follow-up of the BFR14 trial showed that Gleevec (imatinib) remains effective in advanced gastrointestinal stromal ...
CURE

Imfinzi Plus Chemo Improves Survival in G/GEJ Adenocarcinoma

Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo ...